TNF and coronary artery disorder: A pharmacovigilance study using the Food and Drug Administration’s Adverse Event Reporting System indicated an increased reporting of CV events such as strokes and ischemic heart disease among patients with RA treated with JAKis compared with anti-TNF therapies.15